Truvada was the second generation of tenofovir disoproxil fumarate (TDF) drugs, which the FDA approved for Gilead Sciences, Inc. to manufacture and sell in 2004. The formulaic change primarily centered on the addition of emtricitabine, which was later accepted as the first treatment of use as a pre-exposure prophylaxis (PrEP) drug.
The antiretroviral (AR) medication was widely prescribed and sold to thousands of patients in the United States. Current market estimates state that Gilead Sciences earned more than $3 billion annually from Truvada revenue alone.
Truvada and other Tenofovir Disoproxil Fumarate drugs manufactured by Gilead Sciences are the subjects of a 2018 class-action lawsuit filed in California. The Truvada lawsuit alleges that the manufacturer failed to warn patients adequately about the bone and kidney dangers present when taking the drug as prescribed by a physician.
Other Tenofovir Disoproxil Fumarate Drugs that Caused Injury
While Truvada is the most well-recognized brand of TDF medications, there are others that were designed before and after its inception. Injuries stemming from TDF medication use include kidney disease, bone loss, and lactic acidosis. These injuries are life-threatening and significantly impact the lives of people who are experiencing health issues related to taking Truvada and other Tenofovir Disoproxil Fumarate drugs.
If you experienced losses after taking TDFs but aren’t sure if you have a case, a Florida personal injury lawyer can help you understand which options are available to you or your loved one when pursuing compensation for your losses.
Listed below is a compilation of TDF drugs, which are all made by Gilead Sciences, that could have contributed to your health complications.
Viread
Viread was FDA-approved in 2001. It was the first generation of TDF medications marketed by Gilead Sciences to prevent the multiplicative cell division of HIV and Hepatitis B. Aside from common side effects, the manufacturer was aware of its ability to cause kidney and bone damage at the time.
Atripla
Atripla was the third generation of TDF drugs that became FDA-approved in 2006. Gilead Sciences built upon the existing Truvada compound by adding the active ingredient, efavirenz. While the medicine does not cure HIV or AIDS, it was shown to be effective in preventing diseases in non-positive patients.
Complera
Complera was the fourth-generation of TDF drugs manufactured by Gilead Sciences. The FDA approved it as an AR medication in 2011. This iteration of the medicine was a combination of the active ingredients, emtricitabine, rilpivirine, and tenofovir.
Stribild
The fifth and final generation of TDF drugs created by Gilead Sciences was Stribild. The FDA approved Stribild for AR and PrEP use in 2012. Stribild’s active ingredients include cobicistat, elvitegravir, emtricitabine, and tenofovir.
Compensation for Individuals Harmed by Truvada and Other TDF Drugs
Patients who were harmed after taking Truvada or other TDF drugs to prevent the synthesis of HIV, AIDS, hepatitis B, and hepatitis C can pursue compensation related to their losses. Whether it is through the California class-action lawsuit or a Florida civil trial, it is helpful to discuss your experiences and losses with a personal injury lawyer. He or she can help you determine the best course of action for your specific situation.
Contact Chalik & Chalik Injury Lawyers for a No-Obligation Case Review
The partners at Chalik & Chalik Injury Lawyers want you to know that you have legal options available if you or a loved one were injured after taking Truvada or other TDF medications. You are not alone in your fight toward receiving equitable damages. We invite you to contact our office for a free, no-obligation consultation by calling (855) 529-0269 today.
